106 related articles for article (PubMed ID: 20878066)
1. Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
Luo W; Wu F; Elmaoued R; Beck BB; Fischer E; Meng X; Leslie KK; Dai D
Int J Oncol; 2010 Nov; 37(5):1187-94. PubMed ID: 20878066
[TBL] [Abstract][Full Text] [Related]
2. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
[TBL] [Abstract][Full Text] [Related]
3. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Meng X; Laidler LL; Kosmacek EA; Yang S; Xiong Z; Zhu D; Wang X; Dai D; Zhang Y; Wang X; Brachova P; Albitar L; Liu D; Ianzini F; Mackey MA; Leslie KK
Gynecol Oncol; 2013 Mar; 128(3):461-9. PubMed ID: 23146687
[TBL] [Abstract][Full Text] [Related]
4. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
7. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
8. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
10. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
11. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
12. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
13. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
14. Synthetically lethal nanoparticles for treatment of endometrial cancer.
Ebeid K; Meng X; Thiel KW; Do AV; Geary SM; Morris AS; Pham EL; Wongrakpanich A; Chhonker YS; Murry DJ; Leslie KK; Salem AK
Nat Nanotechnol; 2018 Jan; 13(1):72-81. PubMed ID: 29203914
[TBL] [Abstract][Full Text] [Related]
15. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.
Liu Z; Wan G; Heaphy C; Bisoffi M; Griffith JK; Hu CA
Mol Cell Biochem; 2007 Mar; 297(1-2):179-87. PubMed ID: 17119852
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
18. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
19. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer.
Alhaj-Suliman SO; Naguib YW; Wafa EI; Saha S; Ebeid K; Meng X; Mohammed HH; Abuo-Rahma GEA; Yang S; Salem AK
Biomaterials; 2023 May; 296():122093. PubMed ID: 36965280
[TBL] [Abstract][Full Text] [Related]
20. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
